International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

16th Annual Congress - Brisbane 2018

September 16-19, 2018 │ Brisbane, Australia
Brisbane 2018 Congress, Top Science Down Under

yyyy-mm-dd Type Link Title and Presenters

2018-9-17 IATDMCT-Contributed Papers YouTube icon full color

Quantification of metformin in human serum by hydrophilic interaction liquid chromatography - mass spectrometry
Ahmed Abdalla

[+] View Bio

Keywords: TBA

 

Ahmed Abdalla
University of South Australia

 


2018-9-19 IATDMCT-Contributed Papers YouTube icon full color

Loss of control of HIV viremia with OTC weight-loss drugs: A call for caution?
Dario Cattaneo

[+] View Bio

Keywords: HIV, 

 

Dario Cattaneo PhotoDario Cattaneo
Luigi Sacco University Hospital

 

Dr Cattaneo granted Pharmacy degree and post-degree specialization in Pharmacology (University of Milan) and PhD degree (Open University, UK). From 1997 to 2008 he was employed at the Mario Negri Institute for Pharmacological Research, Bergamo, as Head of the Unit of Pharmacology and Pharmacogenetics. Actually, Dr Cattaneo is employed at the Unit of Clinical Pharmacology, Luigi Sacco University Hospital (Milan). From 2012 he is also appointed as assistant professor of Pharmacology, Faculty of Medicine (University of Milan). Dr Cattaneo is Author of nearly 180 scientific articles published in peer-review journals (H-index 34, more than 4500 citations).


2018-9-18 IATDMCT-Contributed papers YouTube icon full color Association of fludarabine exposure and survival after allogeneic cell transplantation: Retrospectively estimated and prospectively simulated
Erik van Maarseveen
[+] View Bio

Keywords:

 

van maarseveen 150x200Erik van Maarseveen
University Medical Center Utrecht

 

Dr. Erik van Maarseveen got his Pharmacy Degree in 2005 and started his career as a pharmacist at the Gouda Hospital (The Netherlands). That same year he obtained the Certificate of Fundamentals of Business & Economics for Beta’s as part of the Master program “Business and Economics for Beta’s” at Utrecht University. His 4-year-training as a hospital pharmacist commenced in 2006 at Central Hospital Pharmacy, The Hague and the Gouda Hospital. Dr. van Maarseveen has been working as a registered hospital pharmacist since 2010 at the University Medical Center Utrecht (The Netherlands), where he leads the therapeutic drug monitoring and toxicology laboratory which is equipped with GC, HPLC, UPLC, LC-MSMS and Orbitrap-LCMS technologies. Dr. van Maarseveen and his team develop bio-analytical assays primarily for therapeutic drug monitoring and clinical toxicology purposes with the ultimate goal to improve treatment outcomes. Directly after he obtained his PhD on optimizing treatment of once daily dosed aminoglycosides and continuously infused vancomycin in 2014, he embarked on his clinical pharmacologist training, which he completed in 2016. Currently, his research focusses on clinical pharmacology and bioanalysis in solid organ and stem cell transplantation, infectious diseases, cystic fibrosis and oncology. Among others, he is co-applicant of a grant of the Dutch KiKa (Children Cancerfree) foundation awarded to investigate the pharmacology of conditioning agents in stem cell transplantation conditioning. Van Maarseveen is a member of the TDM in Oncology scientific committee of the IATDMCT association, chair of the special interest group on Transplantation and member of the committee on Analysis & Toxicology of the Dutch Association for Hospital Pharmacists. In 2016, he was installed as a board member of the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology. Van Maarseveen is a member of pharmacy steering committee of the European Society for Bone Marrow Transplant. Furthermore, Dr van Maarseveen, who is in possession of a university teaching qualification, teaches pharmacology, TDM and toxicology to both pharmacy and medical students at Utrecht University and in 2017 he was elected as a Direction of Education within the IATDMCT association. Dr van Maarseveen has published over 40 peer-reviewed papers (https://www.researchgate.net/profile/Erik_Van_Maarseveen2), acts as a reviewer for multiple clinical and pharmacology journals and has served as an invited speaker and sessions chair on multiple (inter)national congresses. In 2015 he was granted the award for best publication by the Dutch Association for Hospital Pharmacists.


2018-9-18 IATDMCT-Contributed papers YouTube icon full color

Paracetamol use prior to HCT conditioning has a significant effect on the within-patient busulfan pharmacokinetics over time.
Erik van Maarseveen

[+] View Bio

Keywords:

 

van maarseveen 150x200Erik van Maarseveen
University Medical Center Utrecht

 

Dr. Erik van Maarseveen got his Pharmacy Degree in 2005 and started his career as a pharmacist at the Gouda Hospital (The Netherlands). That same year he obtained the Certificate of Fundamentals of Business & Economics for Beta’s as part of the Master program “Business and Economics for Beta’s” at Utrecht University. His 4-year-training as a hospital pharmacist commenced in 2006 at Central Hospital Pharmacy, The Hague and the Gouda Hospital. Dr. van Maarseveen has been working as a registered hospital pharmacist since 2010 at the University Medical Center Utrecht (The Netherlands), where he leads the therapeutic drug monitoring and toxicology laboratory which is equipped with GC, HPLC, UPLC, LC-MSMS and Orbitrap-LCMS technologies. Dr. van Maarseveen and his team develop bio-analytical assays primarily for therapeutic drug monitoring and clinical toxicology purposes with the ultimate goal to improve treatment outcomes. Directly after he obtained his PhD on optimizing treatment of once daily dosed aminoglycosides and continuously infused vancomycin in 2014, he embarked on his clinical pharmacologist training, which he completed in 2016. Currently, his research focusses on clinical pharmacology and bioanalysis in solid organ and stem cell transplantation, infectious diseases, cystic fibrosis and oncology. Among others, he is co-applicant of a grant of the Dutch KiKa (Children Cancerfree) foundation awarded to investigate the pharmacology of conditioning agents in stem cell transplantation conditioning. Van Maarseveen is a member of the TDM in Oncology scientific committee of the IATDMCT association, chair of the special interest group on Transplantation and member of the committee on Analysis & Toxicology of the Dutch Association for Hospital Pharmacists. In 2016, he was installed as a board member of the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology. Van Maarseveen is a member of pharmacy steering committee of the European Society for Bone Marrow Transplant. Furthermore, Dr van Maarseveen, who is in possession of a university teaching qualification, teaches pharmacology, TDM and toxicology to both pharmacy and medical students at Utrecht University and in 2017 he was elected as a Direction of Education within the IATDMCT association. Dr van Maarseveen has published over 40 peer-reviewed papers (https://www.researchgate.net/profile/Erik_Van_Maarseveen2), acts as a reviewer for multiple clinical and pharmacology journals and has served as an invited speaker and sessions chair on multiple (inter)national congresses. In 2015 he was granted the award for best publication by the Dutch Association for Hospital Pharmacists.


2018-9-18 IATDMCT-Contributed Papers YouTube icon full color

Establishment of a national Therapeutic Drug Monitoring (TDM) service for the treatment of challenging childhood cancer patient populations
Gareth Veal

[+] View Bio

Keywords: Childhood cancer; chemotherapy, pharmacokinetics, therapeutic drug monitoring

 

Gareth Veal PhotoGareth Veal
Newcastle University

 

Gareth Veal is Professor of Cancer Pharmacology at the Northern Institute for Cancer Research, Newcastle University, where he heads the Newcastle Cancer Centre Pharmacology Group, a research team with many years of experience in running clinical pharmacology studies relating to both childhood and adult cancer. Key areas for the group include the development of pharmacokinetic and biomarker assays for early phase clinical trials alongside the implementation of therapeutic drug monitoring approaches to treatment in childhood cancer. He is chair of the CCLG Pharmacology Working Group in the UK, responsible for the coordination of a CRUK-funded programme for pharmacology studies in paediatric oncology, and is a member of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), a group established to foster high-quality, ethical research on the quality, safety and efficacy of medicines for use in children. His team were awarded the Quality in Care Excellence in Oncology ‘Best Innovation in Service Provision’ Award for the establishment of a national therapeutic drug monitoring service for the treatment of children with cancer. He has published close to 100 papers and currently has active research grants from Cancer Research UK, the European Commission, the NIHR, the Wellcome Trust and Sarcoma UK.


2018-9-17 IATDMCT-Contributed Papers YouTube icon full color

Detection of synthetic opioids using high resolution mass spectrometry: Keeping up with the trends
Kara Lynch

[+] View Bio

Keywords:

 

Kara Lynch
University of California San Francisco


2018-9-18 IATDMCT-Contributed Papers YouTube icon full color

Clinical validation of a DPD functional test in dried saliva sample as predictor of 5-fluorouracil exposure and severe toxicity
Marina Antunes

[+] View Bio

Keywords:

 

Marina Antunes
Universidade Feevale


2018-9-18 IATDMCT-Contributed Papers YouTube icon full color

The cost-effectiveness of Therapeutic Drug Monitoring (TDM) of generic imatinib for the treatment of Chronic Myelogenous Leukemia (CML)
Salvatore Salamone

[+] View Bio

Keywords: imatinib, TDM, pharmacoeconomic

 

SSalamone PhotoSalvatore Salamone
Saladax Biomedical

 

Dr. Salamone has more than 30 years’ experience in the health care and medical device industries. Prior to founding Saladax in 2004, Dr. Salamone was Vice President of Research and Development at Roche Diagnostics where he was responsible for North American research and development efforts for the Laboratory Systems Division. During his 17-year tenure at Roche, Dr. Salamone’s efforts resulted in the launch of seven major reagent product lines, comprised of more than 70 FDA-approved products and more than 200 instrument applications. At Saladax Dr. Salamone’s group has developed proprietary positions in the field of oncology and psychiatry drug management. These assays address unmet medical needs in providing precision treatment. Dr. Salamone has published extensively in the field of drug monitoring, having authored more than 100 publications, including articles, textbook chapters, books, and is also the holder of 41 issued US patents. He has received numerous awards including the Ben Franklin award for Innovation and in 2016 he was inducted into the prestige’s New Jersey Inventors Hall of Fame. Dr. Salamone earned two bachelor’s degrees from Villanova University, a master’s and a Ph.D degree from Rutgers University and was a Science Engineering Research Council (SERC) Post-Doctoral Fellow at Oxford University.


2018-9-19 IATDMCT-Contributed Papers YouTube icon full color

Vancomycin – Improving prescribing practices
Sophie Stocker

[+] View Bio

Keywords: - vancomcyin, therapeutic drug monitoring, AUC-guided dosing, Bayesian forecasting software

 

Sophie StockerSophie Stocker
St Vincent's Hospital

 

Sophie Stocker is a Senior Hospital Scientist in the Department of Clinical Pharmacology and Toxicology at St Vincent’s Hospital, Sydney. She is also a conjoint lecturer of the St Vincent’s Clinical School, University of New South Wales. Her research program involves clinical and experimental pharmacology, ethnopharmacology, pharmacogenomics, pharmacometrics and qualitative research on the impact of intrinsic and extrinsic factors on drug disposition, efficacy and safety. Her research focuses on understanding variability in response to medicines and how this can be managed to optimise patient care.


2018-9-17 IATDMCT-Contributed Papers YouTube icon full color

Designer benzodiazepines pharmacological effects: how to find the information?
Souleiman El Balkhi

[+] View Bio

Keywords:

 

SBalkhi PhotoSouleiman El Balkhi
University Hospital

 

Souleiman El Balkhi is a toxicologist (PharmD, PhD) at the Hospital University of Limoges in the Pharmacology-Toxicology and Pharmacovigilance Department (PTP) directed by Pr. P. Marquet. He graduated from the Faculty of Pharmacy of Damascus (Syria) in 1999 and obtained his PhD in Toxicology from the Faculty of Pharmacy of Paris Descartes (Paris V) in 2010. He is currently responsible of Environmental Toxicology and Heavy Metals Unit. Since he joined PTP Department at the end of 2014, New Psychoactive Substances (NPS) has been one of his main subjects of interest. As there is a lack of information and data on the effects, the interactions and metabolism of NPS, he started to explore many of these aspects with the help of the PTP team and students. The work presented at the 16th IATDMCT on designer benzodiazepines effects is one of the latest studies that he conducted with the help of his student (F. Herault) for a graduating degree thesis.


2018-9-19 IATDMCT-Contributed Papers YouTube icon full color

Development of ƒ%T>MIC calculation model and its application in individualized medication optimization of carbopenems in critical care patients
Wenqian Chen

[+] View Bio

Keywords: Carbopenems,pharmacokinetics/pharmacodynamics,%T>MIC,Therapeutic drug monitoring

 

Wenqian Chen

China-Japan Friendship Hospital